Improved monitoring of 2-Hydroxyglutarate to stage response of combined Vorasidenib and Tumor Specific Peptide Vaccine therapies in recurrent IDH1 mutant lower grade glioma

Administered By

Awarded By

Contributors

Start/End

  • September 21, 2022 - August 31, 2026